ASX / MEDIA RELEASE **17th March 2015**

Sirtex Reports Preliminary SIRFLOX Study Results

- In the first-line treatment of non-resectable metastatic colorectal cancer:
  - SIRFLOX study does not show a statistically significant improvement in overall Progression-Free Survival.
  - SIRFLOX study does show a statistically significant improvement in Progression-Free Survival in the liver.
- Data to be submitted for peer review to the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting

Sydney, Australia; 17th March 2015 -- Sirtex Medical Limited (ASX: SRX) is pleased to report today the preliminary results of its SIRFLOX clinical study.

Based on the preliminary analysis just completed, the primary endpoint of the SIRFLOX study was not achieved. The preliminary analysis shows that adding SIR-Spheres® Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer (mCRC) does not result in a statistically significant improvement in the overall Progression-Free Survival (PFS). Overall PFS measures progression of existing tumours and/or the development of new tumours in any organ or body site.

Sirtex is pleased that the preliminary analysis showed that SIR-Spheres Y-90 resin microspheres did result in a statistically significant improvement in Progression-Free Survival (PFS) in the liver. This secondary study endpoint is important as liver tumours are commonly the only, or dominant, site of disease in patients with mCRC and are the major site of disease influencing survival. Up to 90% of mCRC patients die of liver failure due to the local effects of the liver tumours [(1)]. SIR-Spheres Y-90 resin microspheres are specifically targeted to treat liver tumours.

As previously advised (most recently on 9th October 2014), the SIRFLOX study results and preliminary analysis still require verification and validation through the process of academic peer review. Presentation at a scientific conference and/or publication in a medical journal are essential parts of this process.

The final results and related detailed analysis of the SIRFLOX study will therefore be submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held 29th May – 2nd June 2015 in Chicago, Illinois.

Reference

(1) Kennedy A; Coldwell D *et al.* Resin ^{90}Y-microsphere brachytherapy for non-resectable colorectal liver metastases: modern USA experience. Int. J. Radiation Oncology Biol. Phys 2006; 65(2): 412-425.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About the SIRFLOX Study
For information, please visit www.sirflox.com, and the ASX announcement made by the Company on October 9th 2014.

About Sirtex Medical Limited
For information, please visit www.sirtex.com

For more information, please contact:
Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com